Trials / Unknown
UnknownNCT04926532
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
An Open-label, Single Arm, Multi-center Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# Toripalimab Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma Cannot Undergo Surgical Resection and TACE
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Detailed description
The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Toripalimab is a humanized anti-PD-1 monoclonal antibody |
| DRUG | Sorafenib | Sorafenib is a multi-kinase inhibitor |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2021-10-31
- Completion
- 2021-12-31
- First posted
- 2021-06-15
- Last updated
- 2021-06-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04926532. Inclusion in this directory is not an endorsement.